IGF1 and metabolic syndrome: In the future, we will examine in all women recruited in the Diana-5 study how IGF-1 levels, insulin resistance, and fasting insulin levels in women without MetS may influence the incidence of relapses, secondary BC, and metastases compared to women diagnosed with MetS.